IMPORTANT SAFETY INFORMATION:
Veripred™ 20 (20 mg prednisolone per 5 mL) is a prescription drug product indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with seasonal or perennial allergic rhinitis; asthma; contact and atopic dermatitis; serum sickness; and drug hypersensitivity reactions. Veripred™ 20 is contraindicated in patients with systemic fungal infections. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Veripred™ 20 may cause mood swings. Adverse effects of Veripred™ 20 include the following: cardiovascular; (hypertrophic cardiomyopathy in premature infants); dermatologic (facial erythema; increased sweating; impaired wound healing; may suppress reactions to skin tests; petechiae and ecchymoses; thin fragile skin; urticaria; edema); endocrine (decreased carbohydrate tolerance; development of cushingoid state; hirsutism; increased requirements for insulin or oral hypoglycemic agents in diabetic patients; manifestations of latent diabetes mellitus; menstrual irregularities; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness; suppression of growth in children); fluid and electrolyte disturbances (congestive heart failure in susceptible patients; fluid retention; hypertension; hypokalemic alkalosis; potassium loss; sodium retention); gastrointestinal (abdominal distention; elevation in serum liver enzyme levels (usually reversible upon discontinuation); pancreatitis; peptic ulcer with possible perforation and hemorrhage; ulcerative esophagitis); metabolic (negative nitrogen balance due to protein catabolism); musculoskeletal (aseptic necrosis of femoral and humeral heads; loss of muscle mass; muscle weakness; osteoporosis; pathologic fracture of long bones; steroid myopathy; tendon rupture; vertebral compression fractures); neurological (convulsions; headache; increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment; psychic disorders; vertigo); ophthalmic (exophthalmos; glaucoma; increased intraocular pressure; posterior subcapsular cataracts); increased appetite; malaise; nausea; and weight gain. For full prescribing information, please click here.

If you do not have Adobe® Acrobat® Reader for viewing the pdfs shown above, you may download it free of charge by clicking here.